UA50719C2 - Проліки для терапії пухлин і запальних захворювань - Google Patents

Проліки для терапії пухлин і запальних захворювань

Info

Publication number
UA50719C2
UA50719C2 UA97031095A UA97031095A UA50719C2 UA 50719 C2 UA50719 C2 UA 50719C2 UA 97031095 A UA97031095 A UA 97031095A UA 97031095 A UA97031095 A UA 97031095A UA 50719 C2 UA50719 C2 UA 50719C2
Authority
UA
Ukraine
Prior art keywords
formula
precursor
inflammation
cancer
therapy
Prior art date
Application number
UA97031095A
Other languages
English (en)
Russian (ru)
Ukrainian (uk)
Inventor
Клаус БОСЛЕТ
Йорг ЧЕХ
Манфред ГЕРКЕН
Райнер ШТРАУБ
Клод Моннере
Жан-Клод Флорен
Фредерік Шмідт
Original Assignee
Авентіс Фарма Дойчланд Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8222555&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA50719(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Авентіс Фарма Дойчланд Гмбх filed Critical Авентіс Фарма Дойчланд Гмбх
Publication of UA50719C2 publication Critical patent/UA50719C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
UA97031095A 1996-03-12 1997-03-11 Проліки для терапії пухлин і запальних захворювань UA50719C2 (uk)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP96103866 1996-03-12

Publications (1)

Publication Number Publication Date
UA50719C2 true UA50719C2 (uk) 2002-11-15

Family

ID=8222555

Family Applications (1)

Application Number Title Priority Date Filing Date
UA97031095A UA50719C2 (uk) 1996-03-12 1997-03-11 Проліки для терапії пухлин і запальних захворювань

Country Status (24)

Country Link
US (1) US5935995A (https=)
EP (1) EP0795334B1 (https=)
JP (1) JP4392065B2 (https=)
KR (1) KR100466467B1 (https=)
CN (1) CN1168733C (https=)
AT (1) ATE316799T1 (https=)
AU (1) AU708202B2 (https=)
BG (1) BG61900B1 (https=)
BR (1) BRPI9701248B1 (https=)
CA (1) CA2199664C (https=)
CZ (1) CZ297994B6 (https=)
DE (1) DE59712561D1 (https=)
DK (1) DK0795334T3 (https=)
ES (1) ES2257756T3 (https=)
HU (1) HU228764B1 (https=)
NO (1) NO320322B1 (https=)
NZ (1) NZ314368A (https=)
PL (1) PL189604B1 (https=)
RO (1) RO120951B1 (https=)
RU (1) RU2191021C2 (https=)
SG (1) SG50011A1 (https=)
SI (1) SI0795334T1 (https=)
TR (1) TR199700178A2 (https=)
UA (1) UA50719C2 (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5525606A (en) 1994-08-01 1996-06-11 The United States Of America As Represented By The Department Of Health And Human Services Substituted 06-benzylguanines and 6(4)-benzyloxypyrimidines
DE19720312A1 (de) * 1997-05-15 1998-11-19 Hoechst Ag Zubereitung mit erhöhter in vivo Verträglichkeit
IL138990A0 (en) * 1999-02-12 2001-11-25 Biostream Inc Matrices for drug delivery and methods for making and using the same
US6716452B1 (en) * 2000-08-22 2004-04-06 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
ES2246234T3 (es) 1999-05-04 2006-02-16 Strakan International Limited Glicosidos de androgenos y actividad androgenica de los mismos.
US6191119B1 (en) * 1999-10-15 2001-02-20 Supergen, Inc. Combination therapy including 9-nitro-20(S)-camptothecin
US8394813B2 (en) 2000-11-14 2013-03-12 Shire Llc Active agent delivery systems and methods for protecting and administering active agents
DE10058596A1 (de) * 2000-11-25 2002-06-06 Aventis Pharma Gmbh Verfahren zum Screening von chemischen Verbindungen zur Modulierung der Wechselwirkung einer EVH1-Domäne oder eines Proteins mit einer EVH1-Domäne mit einer EVH1-Bindedomäne oder einem Protein mit einer EVH1-Bindedomäne sowie ein Verfahren zum Nachweis besagter Wechselwirkung
US20060014697A1 (en) 2001-08-22 2006-01-19 Travis Mickle Pharmaceutical compositions for prevention of overdose or abuse
US7169752B2 (en) 2003-09-30 2007-01-30 New River Pharmaceuticals Inc. Compounds and compositions for prevention of overdose of oxycodone
WO2003018549A2 (en) * 2001-08-30 2003-03-06 Chemocentryx, Inc. Bicyclic compounds as inhibitors of chemokine binding to us28
EP1541579A1 (en) * 2002-06-20 2005-06-15 Nippon Suisan Kaisha, Ltd. Produrg, medicinal utilization thereof and process for producing the same
US8133881B2 (en) 2003-01-13 2012-03-13 Shire Llc Carbohydrate conjugates to prevent abuse of controlled substances
US7160867B2 (en) * 2003-05-16 2007-01-09 Isotechnika, Inc. Rapamycin carbohydrate derivatives
EP1734962A4 (en) * 2004-03-30 2010-07-14 Painceptor Pharma Corp COMPOSITIONS AND METHOD FOR MODULATING CONTROLLED ION CHANNELS
US7825096B2 (en) * 2004-09-08 2010-11-02 The United States Of America As Represented By The Department Of Health And Human Services O6-alkylguanine-DNA alkyltransferase inactivators and beta-glucuronidase cleavable prodrugs
CN102746336B (zh) * 2005-06-29 2015-08-19 施瑞修德制药公司 氨基磷酸酯烷化剂前体药物
ES2547302T3 (es) * 2007-04-06 2015-10-05 Ziopharm Oncology, Inc. Sales de mostaza de isofosforamida y análogos de las mismas
GB0907551D0 (en) * 2009-05-01 2009-06-10 Univ Dundee Treatment or prophylaxis of proliferative conditions
BR112012004720B1 (pt) * 2009-09-02 2021-06-29 Auckland Uniservices Limited Inibidores de cinase, seus usos, profármaco e composição farmacêutica que o compreende
KR101253399B1 (ko) 2010-10-26 2013-04-11 영남대학교 산학협력단 아포지단백질 ａ－ｉ 및 그 변이체를 포함한 재조합 고밀도지단백질을 이용한 라파마이신 제형
KR101628872B1 (ko) 2014-05-28 2016-06-09 주식회사 레고켐 바이오사이언스 자가-희생 기를 포함하는 화합물
HRP20240795T1 (hr) 2015-11-25 2024-09-13 Ligachem Biosciences Inc. Konjugati koji se sastoje od samozapaljujućih skupina i postupci povezani s njima
AU2016359234B2 (en) 2015-11-25 2022-09-08 Ligachem Biosciences Inc. Conjugates comprising peptide groups and methods related thereto
KR102847350B1 (ko) 2015-11-25 2025-08-19 주식회사 리가켐바이오사이언스 분지된 링커를 포함하는 항체-약물 접합체 및 이의 제조방법
CN108367043A (zh) 2015-12-04 2018-08-03 西雅图基因公司 季铵化的微管溶素化合物的缀合物
US11793880B2 (en) 2015-12-04 2023-10-24 Seagen Inc. Conjugates of quaternized tubulysin compounds
MX2019011655A (es) 2017-03-29 2019-12-19 Legochem Biosciences Inc Profarmaco de dimero de pirrolobenzodiazepina y compuesto conjugado ligando-conector de este.
PE20210367A1 (es) 2018-02-02 2021-02-26 Maverix Oncology Inc Conjugados de farmacos de molecula pequena de monofosfato de gemcitabina
JP7459063B2 (ja) 2018-05-09 2024-04-01 レゴケム バイオサイエンシズ， インク． 抗－ｃｄ１９抗体薬物複合体に関連する組成物および方法
KR20210028544A (ko) 2019-09-04 2021-03-12 주식회사 레고켐 바이오사이언스 인간 ror1에 대한 항체를 포함하는 항체 약물 접합체 및 이의 용도

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3836676A1 (de) * 1988-10-28 1990-05-03 Hoechst Ag Die verwendung von 4h-1-benzopyran-4-on-derivaten, neue 4h-1-benzopyran-4-on-derivate und diese enthaltende arzneimittel
US5284856A (en) * 1988-10-28 1994-02-08 Hoechst Aktiengesellschaft Oncogene-encoded kinases inhibition using 4-H-1-benzopyran-4-one derivatives
AU648015B2 (en) * 1989-01-23 1994-04-14 Akzo N.V. Site specific in-vivo activation of therapeutic drugs
DE4106389A1 (de) * 1991-02-28 1992-09-03 Behringwerke Ag Fusionsproteine zur prodrug-aktivierung, ihre herstellung und verwendung
DE59010701D1 (de) * 1990-05-18 1997-05-22 Hoechst Ag Isoxazol-4-carbonsäureamide und hydroxyalkyliden-cyanessigsäureamide, diese verbindungen enthaltende arzneimittel und deren verwendung
FR2676058B1 (fr) * 1991-04-30 1994-02-25 Hoechst Lab Prodrogues glycosylees, leur procede de preparation et leur utilisation dans le traitement des cancers.
EP0538799B1 (en) * 1991-10-25 1995-03-15 TUNGSRAM Részvénytársaság Single-capped low-pressure discharge lamp
DE4233152A1 (de) * 1992-10-02 1994-04-07 Behringwerke Ag Antikörper-Enzym-Konjugate zur Prodrug-Aktivierung
CA2081281A1 (en) * 1992-10-23 1994-04-24 Shing-Ming Wang Activation of glucuronide prodrugs by ligand-beta-glucuronidase conjugates for chemotherapy
DE4236237A1 (de) * 1992-10-27 1994-04-28 Behringwerke Ag Prodrugs, ihre Herstellung und Verwendung als Arzneimittel
DE4314556A1 (de) * 1993-05-04 1994-11-10 Behringwerke Ag Modifizierte Antikörperenzymkonjugate und Fusionsproteine sowie ihre Anwendung zur tumorselektiven Therapie
EP0647450A1 (en) * 1993-09-09 1995-04-12 BEHRINGWERKE Aktiengesellschaft Improved prodrugs for enzyme mediated activation
DE4417865A1 (de) * 1994-05-20 1995-11-23 Behringwerke Ag Kombination von Tumornekrose-induzierenden Substanzen mit Substanzen, die durch Nekrosen aktiviert werden, zur selektiven Tumortherapie

Also Published As

Publication number Publication date
HU228764B1 (en) 2013-05-28
CN1168733C (zh) 2004-09-29
HU9700579D0 (en) 1997-04-28
AU708202B2 (en) 1999-07-29
CN1163895A (zh) 1997-11-05
SG50011A1 (en) 1998-06-15
NZ314368A (en) 1998-10-28
HUP9700579A2 (en) 1997-12-29
CA2199664A1 (en) 1997-09-12
TR199700178A2 (tr) 1997-09-21
SI0795334T1 (sl) 2006-06-30
BG101290A (en) 1997-09-30
CZ297994B6 (cs) 2007-05-16
CZ74297A3 (en) 1997-09-17
DE59712561D1 (de) 2006-04-13
EP0795334B1 (de) 2006-02-01
MX9701832A (es) 1998-07-31
NO971116D0 (no) 1997-03-11
BG61900B1 (bg) 1998-09-30
BR9701248A (pt) 1999-10-13
ATE316799T1 (de) 2006-02-15
JP4392065B2 (ja) 2009-12-24
BR9701248A8 (pt) 2013-06-18
RU2191021C2 (ru) 2002-10-20
EP0795334A2 (de) 1997-09-17
CA2199664C (en) 2008-05-20
PL189604B1 (pl) 2005-08-31
US5935995A (en) 1999-08-10
NO320322B1 (no) 2005-11-21
EP0795334A3 (de) 1997-09-24
JPH101495A (ja) 1998-01-06
ES2257756T3 (es) 2006-08-01
HUP9700579A3 (en) 1999-05-28
KR100466467B1 (ko) 2005-06-29
AU1620597A (en) 1997-09-18
DK0795334T3 (da) 2006-06-06
PL318878A1 (en) 1997-09-15
BRPI9701248B1 (pt) 2022-01-18
NO971116L (no) 1997-09-15
RO120951B1 (ro) 2006-10-30
KR970065550A (ko) 1997-10-13

Similar Documents

Publication Publication Date Title
UA50719C2 (uk) Проліки для терапії пухлин і запальних захворювань
CY1105707T1 (el) Συνδυασμοι φορμοτερολης και ενος αλατος τριοτροπιου
TR199901417T2 (xx) Analjezik etkisi olan yeni bile�imler.
EE9700195A (et) Peroraalne farmatseutiline annusvorm, mis sisaldab prootonpumba inhibiitorit ja prokineetilist ainet
NO20053105D0 (no) Oral, analgesisk doseringsform med forlenget frigivelse for administrering ±n gang pr. dag.
SE9504661D0 (sv) New compounds
CY1111153T1 (el) Μορφη οσμοτικης δοσολογιας παρατεταμενης απελευθερωσης
DE69831869D1 (de) Verbesserte verabreichungstechnik für multiple medikamentengaben
EE9700192A (et) Peroraalne farmatseutiline annusvorm, mis sisaldab prootonpumba inhibiitorit ja antatsiidainet või alginaati
CL2009001682A1 (es) Composición farmacéutica espontáneamente dispersable para administración oral que comprende n-benzoil-estaurosporina; método para incrementar los niveles de biodisponibilidad. (divisional de la solocitud 333-00).
BR0315337A (pt) Composto, formulação farmacêutica, e, método para tratar câncer
DK1365808T3 (da) Sammensætninger til antitumorbehandling indeholdende ecteinascidin 743
SE9900961D0 (sv) Novel compounds
DE60019334D1 (de) Antivirale arznei
EE04606B1 (et) H+, K+-ATPaasi inhibiitori kasutamine ravimi valmistamiseks peroraalseks manustamiseks
BR0012901A (pt) Medicamentos de ß - carbolina
SE9802208D0 (sv) Novel compounds
ES2135342B1 (es) Uso del raloxifeno o una sal o salvato del mismo en la preparacion de un medicamento para prevenir el cancer de mama.
ATE268174T1 (de) Sibutramin und orlistat enthaltende pharmazeutische zusammensetzungen
BR0007452A (pt) Uso de melagatrano ou de um derivado farmaceuticamente aceitável ou pró-droga do mesmo, método de tratamento de inflamação, e, formulação farmacêutica para uso no tratamento de inflamação
ATE356637T1 (de) Supramolekulare komplexe enthaltende arzneimittel
ATE360428T1 (de) Analgetisches arzneimittel
TR200102512T2 (tr) Tüm ruhsal bozukluklar, adaptasyon bozuklukları ve çeşitli kaygı-depresyon bozukluklarının tedavisinde ya da önlenmesinde yararlı tıbbi ürünlerin hazırlanması için saredutan ve onun farmasötik olarak kabul edilebilir tuzlarının kullanımı.
SE9802209D0 (sv) Novel compounds
NO20031410L (no) Anvendelse av distamycinderivater for fremstilling av medikamenter